Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

One year outcomes of LASIK for mixed cylinder using the MEL 90 excimer laser

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Keratorefractive Results I

Venue: Poster Village: Pod 2

First Author: : A.Day UK

Co Author(s): :    D. Reinstein   G. Carp   T. Archer        

Abstract Details

Purpose:

To report the outcomes of LASIK for mixed cylinder using the Triple-A ablation profile with the MEL 90 excimer laser (Carl Zeiss Meditec).

Setting:

London Vision Clinic, London, UK.

Methods:

This was a retrospective analysis of 105 consecutive eyes (82 patients) treated by LASIK for mixed cylinder using Triple-A ablation profile with the MEL 90. Patients were followed for 1 year after surgery. Standard outcomes analysis and vector analysis by the Alpins method was performed.

Results:

Mean attempted SEQ was 0.30±0.90D (-2.30 to +1.75D). Mean cylinder was 2.93±1.47D (0.75 to 7.00D). Preop CDVA was 20/20 or better in 81% of eyes. Postop UDVA was 20/20 or better in 69% and 20/25 or better in 86% of eyes. Mean postop SEQ relative to the intended target was -0.21±0.38D (-1.25 to +1.13D), with 83% within ±0.50D. Mean postop cylinder was 0.57±0.41D (0.00 to 1.75D). For angle of error, the arithmetic mean was -0.6±4.2˚, the absolute mean was 2.9±3.0˚. Three percent eyes lost 1 line CDVA, no eyes lost ≥2 lines CDVA.

Conclusions:

One year outcomes of LASIK using the MEL 90 for mixed cylinder up to 7.00D demonstrated excellent efficacy, safety, and predictability. Vector analysis found a 12% overcorrection in magnitude. Given the high accuracy for angle of error, a nomogram could be applied to reduce the overcorrection.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous